PUBLISHER: The Business Research Company | PRODUCT CODE: 1946645
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946645
Oncology molecular diagnostics involve tests that analyze genes, proteins, and related molecules to diagnose cancers and guide treatment decisions.
The primary products in the oncology molecular diagnostics market include instruments, reagents, and others. Oncology molecular diagnostic instruments are utilized for the detection and diagnosis of cancer. The technologies involved include polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermal nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectrometry, transcription-mediated amplification (TMA), and others. These products are used by end users such as hospitals, diagnostic centers, academic institutions, research organizations, and others.
Tariffs are impacting the oncology molecular diagnostics market by increasing costs of imported sequencing instruments, reagents, and analytical software components. Reagents and instruments segments are most impacted, especially in North America and Asia-Pacific where advanced diagnostics are widely deployed. Elevated costs may delay technology upgrades for diagnostic centers. Conversely, tariffs are encouraging regional manufacturing, domestic reagent production, and strategic collaborations to reduce dependency on imports.
The oncology molecular diagnostics market research report is one of a series of new reports from The Business Research Company that provides oncology molecular diagnostics market statistics, including oncology molecular diagnostics industry global market size, regional shares, competitors with a oncology molecular diagnostics market share, detailed oncology molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the oncology molecular diagnostics industry. This oncology molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncology molecular diagnostics market size has grown rapidly in recent years. It will grow from $5.65 billion in 2025 to $6.34 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing cancer prevalence, adoption of PCR and sequencing, oncology research funding, hospital diagnostic expansion, regulatory approvals for molecular tests.
The oncology molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to precision oncology adoption, liquid biopsy advancements, personalized treatment demand, AI-driven data interpretation, emerging market penetration. Major trends in the forecast period include growth in companion diagnostics, rising use of liquid biopsy, expansion of biomarker-based testing, increasing cancer screening programs, demand for early and accurate cancer detection.
The increasing demand for personalized medicine is increasingly supporting the expansion of the oncology molecular diagnostics market going forward. Personalized medicine focuses on tailoring medical treatments and interventions to individual patient characteristics, including genetic makeup and disease profiles. Oncology molecular diagnostics play a critical role in personalized cancer care by enabling precise tumor profiling, optimized drug selection, and individualized treatment strategies that improve clinical outcomes and patient quality of life. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Consequently, the rising adoption of personalized medicine is strengthening the oncology molecular diagnostics market.
Leading companies operating in the oncology molecular diagnostics market are advancing genomics technologies such as next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling to improve early cancer detection, mutation identification, and personalized treatment strategies. These advancements enhance diagnostic accuracy, reduce turnaround times, and address growing demand for localized, high-precision molecular testing. For example, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE through a collaboration with Burjeel Holdings. The facility enables advanced molecular and immunology testing to be performed locally, strengthening regional diagnostic capabilities and supporting assays for multiple cancers, including prostate cancer through partnerships such as its collaboration on the ClarityDX Prostate test.
In June 2023, INEX Innovate Pte Ltd., a Singapore-based molecular diagnostic technology company, acquired Yourgene Health (Taiwan) Co., Ltd. for an undisclosed amount. Through this acquisition, INEX Innovate aims to strengthen its capabilities in fetal health, oncology research and development, and bioinformatics. Yourgene Health is a Taiwan-based genomics company and international molecular diagnostics group expanding its genetic testing portfolio to include oncology applications.
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMerieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the oncology molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Oncology Molecular Diagnostics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses oncology molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for oncology molecular diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology molecular diagnostics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.